Nature Reviews Cancer

Article	Citations
Targeting ferroptosis as a vulnerability in cancer	1014
Cancer metabolism: looking forward	884
Therapeutic cancer vaccines	827
Systemic immunity in cancer	746
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion	715
The role of ROS in tumour development and progression	702
RNA in cancer	697
Connecting copper and cancer: from transition metal signalling to metalloplasia	665
Endoplasmic reticulum stress signals in the tumour and its microenvironment	638
The matrix in cancer	549
The rediscovery of platinum-based cancer therapy	536
The metabolism of cancer cells during metastasis	526
Recent advances and discoveries in the mechanisms and functions of CAR T cells	520
Interleukins in cancer: from biology to therapy	404
Long noncoding RNAs in cancer metastasis	398
Advances in bladder cancer biology and therapy	372
Exploiting senescence for the treatment of cancer	369
Non-genetic mechanisms of therapeutic resistance in cancer	340
Natural killer cells in antitumour adoptive cell immunotherapy	322
Linking EMT programmes to normal and neoplastic epithelial stem cells	316
Advancing targeted protein degradation for cancer therapy	304
Cancer stem cell–immune cell crosstalk in tumour progression	303
The immunological and metabolic landscape in primary and metastatic liver cancer	279
Targeting DNA damage response pathways in cancer	279
Mutations and mechanisms of WNT pathway tumour suppressors in cancer	258

Harnessing multimodal data integration to advance precision oncology	232
Cancer progression and the invisible phase of metastatic colonization	231
Autophagy in tumour immunity and therapy	227
The language of chromatin modification in human cancers	220
CRISPR in cancer biology and therapy	213
Targeting CDK4 and CDK6 in cancer	209
Designing deep learning studies in cancer diagnostics	205
Cancer nanomedicine	194
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	194
Tumour fatty acid metabolism in the context of therapy resistance and obesity	191
Targeting FAK in anticancer combination therapies	187
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities	184
Programmed death ligand 1 signals in cancer cells	183
Genetic and non-genetic clonal diversity in cancer evolution	181
MYC protein interactors in gene transcription and cancer	176
Liquid–liquid phase separation drives cellular function and dysfunction in cancer	173
A timeline of tumour-associated macrophage biology	169
Targeting the DNA damage response in immuno-oncology: developments and opportunities	168
Overcoming TGFβ-mediated immune evasion in cancer	165
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	165
Antitumour immunity regulated by aberrant ERBB family signalling	162
Sex disparities matter in cancer development and therapy	159
Mutational signatures: emerging concepts, caveats and clinical applications	155
Clonal expansion in non-cancer tissues	150
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance	150
RNA splicing dysregulation and the hallmarks of cancer	145
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer	144
2-Oxoglutarate-dependent dioxygenases in cancer	142
Stress and cancer: mechanisms, significance and future directions	141
The plasticity of mRNA translation during cancer progression and therapy resistance	135
Mitochondrial DNA variation and cancer	132
Polyamines in cancer: integrating organismal metabolism and antitumour immunity	130
Dynamics and specificities of T cells in cancer immunotherapy	127
Aneuploidy as a promoter and suppressor of malignant growth	127
Mechanisms of immune activation and regulation: lessons from melanoma	120
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment	118
mRNA-based cancer therapeutics	117
Big data in basic and translational cancer research	114
Artificial intelligence in cancer research, diagnosis and therapy	109
Glial and myeloid heterogeneity in the brain tumour microenvironment	108
Cancer proteogenomics: current impact and future prospects	105
Biology, vulnerabilities and clinical applications of circulating tumour cells	104
Advances in germline predisposition to acute leukaemias and myeloid neoplasms	103
Synthetic biomarkers: a twenty-first century path to early cancer detection	102
Nucleotide metabolism: a pan-cancer metabolic dependency	101
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	97
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention	96
STAT proteins in cancer: orchestration of metabolism	96
Decoding leader cells in collective cancer invasion	93
Therapeutic targeting of tumour myeloid cells	92

Mapping the genomic diaspora of gastric cancer	91
Targeting the gut microbiota for cancer therapy	91
Leukaemia: a model metastatic disease	90
The coming decade in precision oncology: six riddles	88
Mechanisms driving the immunoregulatory function of cancer cells	84
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment	83
Acetyl-CoA metabolism in cancer	76
Targeting transcription cycles in cancer	73
Developing dietary interventions as therapy for cancer	71
Evolving cancer–niche interactions and therapeutic targets during bone metastasis	68
Bacteria in cancer initiation, promotion and progression	67
Non-coding driver mutations in human cancer	67
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation	65
Context-dependent functions of pattern recognition receptors in cancer	63
Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity	60
Tissue clearing to examine tumour complexity in three dimensions	60
Nonsense-mediated RNA decay: an emerging modulator of malignancy	59
Cancers make their own luck: theories of cancer origins	58
Insights into recent findings and clinical application of YAP and TAZ in cancer	57
Disconnecting multicellular networks in brain tumours	56
Leveraging the replication stress response to optimize cancer therapy	52
Endocytosis in cancer and cancer therapy	49
Tumour–host interactions through the lens of Drosophila	47
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	46
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	45
Solid tumours hijack the histone variant network	44
3D bioprinted cancer models: from basic biology to drug development	44
Aristolochic acid-associated cancers: a public health risk in need of global action	43
Intravital imaging to study cancer progression and metastasis	42
Epithelial and stromal co-evolution and complicity in pancreatic cancer	41
Advances in PET imaging of cancer	41
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters	40
Structural variations in cancer and the 3D genome	39
Equivocal, explicit and emergent actions of PKC isoforms in cancer	39
Deubiquitinases in cancer	39
Evolution and progression of Barrett’s oesophagus to oesophageal cancer	38
The journey from melanocytes to melanoma	37
Removing global barriers to cervical cancer prevention and moving towards elimination	36
Advances in cutaneous squamous cell carcinoma	34
The advent of immune stimulating CAFs in cancer	33
Rethinking cancer targeting strategies in the era of smart cell therapeutics	33
The biology of ependymomas and emerging novel therapies	32
Oncofetal reprogramming in tumour development and progression	31
The neural addiction of cancer	29
Stem-like exhausted and memory CD8+ T cells in cancer	28
Therapeutic resistance to anti-oestrogen therapy in breast cancer	26
Dissecting metastasis using preclinical models and methods	26
How chemokines organize the tumour microenvironment	25
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity	25
How protons pave the way to aggressive cancers	21
Eph receptors and ephrins in cancer progression	21
Metabolic pathway analysis using stable isotopes in patients with cancer	20
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity	20
Bridging live-cell imaging and next-generation cancer treatment	19
Defining and using immune archetypes to classify and treat cancer	19
Gut instinct: a call to study the biology of early-onset colorectal cancer disparities	18
Linking cell mechanical memory and cancer metastasis	18
Nanotherapy: targeting the tumour microenvironment	17
The dynamic role of platelets in cancer progression and their therapeutic implications	17
Pathogenesis of cancers derived from thyroid follicular cells	16
Learning to distinguish progressive and non-progressive ductal carcinoma in situ	16
A guide to artificial intelligence for cancer researchers	16
Mastering the use of cellular barcoding to explore cancer heterogeneity	15
Towards targeting transposable elements for cancer therapy	13
Colorectal cancer subtyping	13
Translating p53-based therapies for cancer into the clinic	13
New targets in triple-negative breast cancer	13
Polygenic scores in cancer	13
Micro-engineering and nano-engineering approaches to investigate tumour ecosystems	11
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	11
Transfer RNAs as dynamic and critical regulators of cancer progression	11
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	10
Gut microbiome immaturity and childhood acute lymphoblastic leukaemia	10
Addressing the mental health crisis	10
EMT in chemoresistance	10
Publisher Correction: Mutations and mechanisms of WNT pathway tumour suppressors in cancer	10
Un-Fair Skin: racial disparities in acral melanoma research	9
Combinatorial strategies to target RAS-driven cancers	9
ATO stabilizes structural p53 mutants	9
Fcγ receptors and immunomodulatory antibodies in cancer	9

The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment	9
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	9
Targeting sex steroid biosynthesis for breast and prostate cancer therapy	7
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours	7
Making cancer research more inclusive	7
Multiplex protein imaging in tumour biology	7
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications	7
Let’s get critical: bringing Critical Race Theory into cancer research	7
Targeting cancer cell dormancy	6
Porcine cancer models for clinical translation	6
Overcoming hurdles in cancer immunotherapy	6
Extrachromosomal DNA in cancer	6
EGFR is going circular	5
The link between vitamin D and prostate cancer	5
Impact of COVID-19 on in vivo work and patient sample availability for cancer research	5
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic	5
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets	5
Peto’s paradox put to the test	5
Decoding the basis of histological variation in human cancer	5
Tertiary lymphoid structures as hubs of antitumour immunity	5
Promoting cancer genomics research in Africa: a roadmap	4
SETDB1, a new target for immunotherapy	4
Obesity-induced neutrophil reprogramming	4
The microbiome as a determinant of racial and ethnic cancer disparities	4
Bispecifics target cancers’ most wanted	4
Liver metastases cultivate an immune desert	4
Neutrophils: a roadblock for immunotherapy	4
Tracing the origins of KRAS oncogene addiction	4
Expanding oesophageal cancer research and care in eastern Africa	4
Addressing systemic racism as the cancer of Black people: equity ethic-driven research	4
Cells are Us – combining research and public engagement	3
Tracking dormant disseminated tumour cells	3
Metastases arrive at other organs via bone	3
Long-range gene regulation in hormone-dependent cancer	3
INVADEseq to study the intratumoural microbiota at host single-cell resolution	3
Air pollution promotes tumorigenesis through pre-existing oncogenic mutations	3
Advances in translational research of the rare cancer type adrenocortical carcinoma	3
Fungi in cancer: not such a ‘fun-guy’	3
Reflecting on 20 years of progress	3
Cancer burden in low-income and middle-income countries	3
T cell drivers in NASH-HCC	3
Personal regulome navigation of cancer	3
Studying extrachromosomal DNA with the ecTag method	3
Lifestyle interventions for cancer survivors	3
Publisher Correction: Programmed death ligand 1 signals in cancer cells	3
IgA strikes twice in ovarian cancer	2
Tumour avatars to model patients’ responses to immunotherapy	2
Functional lineage tracing to study the clonal evolution of therapy resistance	2
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment	2
Blebs signal survival	2
Naughty neutrophils	2
Hunting down rare drug-tolerant cycling cells with Watermelon	2
METTL3 inhibition enhances anti-tumour immunity	2
Integrating microbiomics in cancer management	2
Platelets limit liver tumours	2
tRNA supply and demand	2
Microbiota links to immunotherapy toxicity	2
Quantum probes in cancer research	2
The ways in which carcinogens work	2
Mechanosurveillance of tumour metastasis	2
Taming TAMs in brain metastases	2
Next-generation epidemiologic cohorts for cancer aetiology	2
Stromal cells drive tumorigenesis in BRCA1 mutation carriers	2
Cancer therapy with antibodies	2
Improving understanding of cancer in the gender diverse population	2
Developmental origins shape the paediatric cancer genome	2
CAF-induced physical constraints controlling T cell state and localization in solid tumours	2
Approaching cancer during pregnancy	2
Why do patients with cancer die?	2
Tracking genome evolution following p53 inactivation	2
The neuronal-metabolic interface	2
Understanding and addressing race disparities in childhood cancer outcomes	2
AR in immunotherapy	2
Cycling persister cells	2
Guardrails for the use of generalist AI in cancer care	2
Funding bodies should foster partnerships between industry and academia	2